Imperial.tech

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.

Abingdon Health is an innovative technology-led company focused on providing rapid and near-patient medical diagnostic testing solutions.

Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countries to prevent fraud and financial crime. ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.

Aqdot‘s technology allows for an energy- and raw material-efficient way of manufacturing microcapsules, leading to lower energy consumption and less waste. Potential applications include encapsulating enzymes in laundry detergents, or encapsulating fertilisers in the agrochemical sector. Microencapsulation is a multi-billion-per-annum industry with established applications in household and personal care, food and agrochemical markets.

Silicon Microgravity Limited is a spin-out from Cambridge University. The underpinning sensor technology was developed through a collaboration with BP plc and provides a breakthrough in the management of oil and gas reservoirs. The technology has been developed in Cambridge University’s Nanoscience Centre primarily funded by BP and Innovate UK.

Import.io is the number one Web Data Integration provider. Import.io deliver the world’s data directly to enterprises, fueling business insight and competitive advantage. The Import.io Web Data Integration solution extracts, prepares and integrates high-quality comprehensive web data into customers’ analytics platforms and business applications. The company delivers data to more than 850 customers from millions of web sources.

Kesios Therapeutics Limited develops small molecule drugs for haematological malignancies, such as multiple myeloma and related indications. The company was incorporated in 2012 and is based in London, United Kingdom.

Telectic they provide AI capability to read the web and uncover hard to find B2B prospects, map emerging sectors, segment accounts and monitor companies on particular topics or signals. They have developed a crawler that understands the content from the web, reading company websites, news, social media, academic, official, and other sources.

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

Abingdon Health is an innovative technology-led company focused on providing rapid and near-patient medical diagnostic testing solutions.

Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to improve the lives of cancer patients. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics that will allow a patient's immune system to recognize, attack, and clear their cancer.

Kesios Therapeutics Limited develops small molecule drugs for haematological malignancies, such as multiple myeloma and related indications. The company was incorporated in 2012 and is based in London, United Kingdom.

Lontra is a leading engineering, manufacturing and digital services business delivering revolutionary air and gas compressors. The company is backed by world-class technical and commercial partners, including Industrial Air Centers, Universal Wolf, Sulzer, Shield Engineering Group, ABB, SKF, Severn Trent Water and Yaskawa. The company's flagship product, the award-winning and patented Blade Compressor® is the first widely applicable new compressor design in over 80 years. The technology is proven to be up to a third more efficient than its competitors, offering incredible energy savings and delivering significant improvements in reliability. Now developing new technologies and expanding into new industries and compressor applications. These include general manufacturing, cement, food and drink, pharmaceutical, industrial wastewater, drinking water and power generation. Lontra has attracted wonderful support in terms of grants and awards from Innovate UK, Horizon2020, Edie, IMechE, Royal Academy of Engineering, The Carbon Trust, and Severn Trent Water. Most recently winning the 2020 IMechE Award for Innovation in Bulk Materials and Handling.

Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countries to prevent fraud and financial crime. ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.

Puridify conducts research and development activities on bioprocessing technologies aimed at advancing industrial biomolecule manufacture. The company was founded by Tom Haywood, Oliver Hardick, and Iwan Roberts in March 2013 and is based in United Kingdom.

Yoyo Wallet is a U.K.-based mobile wallet startup that enables its users to pay for their goods with their smartphones. The company currently processes over 150,000 monthly in-store transactions by combining payment and loyalty via an easy scan. It also provides a marketing platform for retailers that enables digital customer engagement in-store. The multi-retailer mobile wallet offers loyalty programs and rewards offerings it can automatically deliver to customers based on buying patterns. Launched in 2013, Yoyo Wallet receives funding from Taavet Hinrikus and TransferWise.

Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms. The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments that retain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.

TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.

Econic Technologies was born from a vision where catalyst chemistry is used to turn waste CO2 into positive economic and environmental potential. Incorporating waste CO2 as a feedstock for polymer preparation using our novel catalysts reduces the reliance on expensive fossil fuels, turning scientific research into business advantage for plastics manufacturers while delivering environmental gain for the benefit of all. This vision was crystallized by Professor Charlotte Williams, then at Imperial College London, and now Professor of Inorganic Chemistry in the Department of Chemistry at the University of Oxford. It was initially supported by investment from Touchstone Innovations, now IP Group plc, and Norner Verdandi, and now includes backing by Woodford Investment Management, Jetstream Capital, and OGCI Climate Investments. Much progress has been made since then. Econic’s catalyst technologies have been patented, validated in pilot operations and continue to secure additional investment. A talented team of scientists, engineers, and commercial managers now conduct their cutting-edge work in a state-of-the-art facility at Alderley Park, the internationally renowned science hub south of Manchester. All of our efforts are intently focused on the future. A future where waste CO2, a damaging greenhouse gas, is turned into a commercial and environmental gain. A future that starts now.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Plaxica is a technology and licensing company focused on the production of next generation biopolymers and platform chemicals from renewable resources. It was founded in 2008 and is based in London and Wilton.

Yoyo Wallet is a U.K.-based mobile wallet startup that enables its users to pay for their goods with their smartphones. The company currently processes over 150,000 monthly in-store transactions by combining payment and loyalty via an easy scan. It also provides a marketing platform for retailers that enables digital customer engagement in-store. The multi-retailer mobile wallet offers loyalty programs and rewards offerings it can automatically deliver to customers based on buying patterns. Launched in 2013, Yoyo Wallet receives funding from Taavet Hinrikus and TransferWise.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Musicmetric offers detailed analytics and trend forecasting for the music industry. Musicmetric is creating software tools and services using machine learning algorithms designed to measure online buzz and deliver relevant analytics. Their tools enable deep analysis of marketing performance, designed to add efficiency and accurate campaign targeting. Additionally, their software offers predictive trend forecasting for artists, genres and sales within the mainstream label, indie and unsigned sectors of the music industry. The company processes terabytes of raw text daily and performs data mining and classification analysis to generate the data which powers its software products. It is also releasing a suite of free widgets powered by the data generated in the back end, as well as opening an API to allow third parties to build applications on top of the musicmetric data. The customer base includes labels, A&R, managers, promoters and marketing agencies.

Acunu Analytics offers a platform for low-latency, continuous analytics on big data; powering dashboards and embedded applications to monitor and control environments in manufacturing, telecommunications, media, financial services and other industries where high-velocity data must be analysed in real time. The Cassandra NoSQL database is at the core of the Acunu offering and Acunu is a very engaged Cassandra contributor donating many of its innovations back to the community. Acunu was founded in 2009 and is backed by some of Europe’s top VC funds. Started by a unique mix of researchers and engineers from Cambridge and Oxford Universities, Acunu has offices in London (near Old Street, London’s “Silicon Roundabout”) and California.

Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.

Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).

Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countries to prevent fraud and financial crime. ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.

Abingdon Health is an innovative technology-led company focused on providing rapid and near-patient medical diagnostic testing solutions.

Cambridge Communication Systems Ltd (CCS), a Cambridge, UK-based newly formed technology company that intends to provide a cost-effective backhaul solution for the mobile infrastructure.

Epsilon-3 Bio Ltd. is a preclinical stage company with investment from Index Ventures, Novo Ventures and Imperial Innovations. The company is focused on the efficient development of first in class drug candidates stimulating safe removal of cellular debris. Such agents are expected to provide a useful treatment for a wide range of diseases including inflammation and autoimmunity, neurodegeneration, fibrosis and cancer.

Chirp's mission is to simplify connectivity using sound. Our machine-to-machine communications software enables any device with a loudspeaker or microphone to exchange data via inaudible sound waves. Driven by unparalleled research and a world-class engineering team, Chirp enables the interconnection of millions of devices in a seamless, scalable, and cost-effective way to enhance end-user experience and add value to existing hardware. To learn more about Chirp, visit https://chirp.io.

Plaxica is a technology and licensing company focused on the production of next generation biopolymers and platform chemicals from renewable resources. It was founded in 2008 and is based in London and Wilton.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.

Nexeon is a leading international developer and manufacturer of breakthrough silicon-based anode materials for rechargeable lithium-ion batteries. These are fundamental to the achievement of ‘net zero’ and a sustainable environment. Nexeon’s battery materials enable significantly higher cell energy density, allowing the design of lighter, smaller and more cost effective batteries. In turn, this leads to enhanced performance for an increasing range of diverse consumer and commercial markets, including electric vehicles, where range and charging times can beneficially be impacted. Nexeon is based in Oxfordshire with operations in Japan. It has a well-established multi-disciplinary technical team with a wide range of expertise. For more details, please visit https://www.nexeon.co.uk

Stanmore Implants Worldwide is an innovative orthopaedic business focused on the design and manufacture of both bespoke and modular implants for limb-sparing and complex primary and revision joint replacement. Stanmore Implants Worldwide designs, manufactures and markets a custom implant service alongside a portfolio of orthopaedic implants for limb salvage and complex joint replacement, and is known for creating some of the world's most successful implants. Stanmore Implants Worldwide acquired its robotic bone preparation technology through the acquisition of Acrobot, a medical devices company specializing in computer-assisted orthopaedic surgery in August 2010. Stanmore Implants Worldwide was acquired by Stryker on April 29, 2016. It was founded in 1948 and is headquartered in London, UK.

Circassia is a dedicated diagnostics and management company focused on asthma. Our market-leading NIOX® products are used by physicians around the world to help improve asthma diagnosis and management, and we support our customers with dedication to outstanding customer service and after sales support. Our purpose is to improve the quality of life for millions of people suffering from asthma. As the leading provider of point-of-care FeNO diagnosis and management products we are making good progress, helping healthcare professionals manage their patients’ asthma. We believe every asthma patient should have access to the best care. To help achieve this, we are working hard to provide our customers with outstanding support, while devoting ourselves to developing the next generation of NIOX® innovations.

Novacem Limited, a London, UK-based developer of a cement based on magnesium oxide which has the potential to transform the cement industry from being a significant emitter of CO2 to being an absorber of CO2.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.

Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to improve the lives of cancer patients. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics that will allow a patient's immune system to recognize, attack, and clear their cancer.

BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in 2007. The company was incorporated in 2006 and is based in London, the United Kingdom.

Plaxica is a technology and licensing company focused on the production of next generation biopolymers and platform chemicals from renewable resources. It was founded in 2008 and is based in London and Wilton.

Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.

Novacem Limited, a London, UK-based developer of a cement based on magnesium oxide which has the potential to transform the cement industry from being a significant emitter of CO2 to being an absorber of CO2.

Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.

Circassia is a dedicated diagnostics and management company focused on asthma. Our market-leading NIOX® products are used by physicians around the world to help improve asthma diagnosis and management, and we support our customers with dedication to outstanding customer service and after sales support. Our purpose is to improve the quality of life for millions of people suffering from asthma. As the leading provider of point-of-care FeNO diagnosis and management products we are making good progress, helping healthcare professionals manage their patients’ asthma. We believe every asthma patient should have access to the best care. To help achieve this, we are working hard to provide our customers with outstanding support, while devoting ourselves to developing the next generation of NIOX® innovations.

Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

InforSense, Ltd. provides enterprise business intelligence and reporting software. Its products include core technology, such as InforSense Platform that enables organizations to integrate, automate, and visualize data sources, information, and analysis processes to deliver predictive insights. Its core technology products also include VisualSense, advanced analytics, reporting, TextSense, document explore, automation, workflow library, In-Oracle edition, Siebel edition, and virtual machine. The company also provides Life Science Applications products, such as ClinicalSense, a clinical research software application for cohort identification for clinical researchers; GenSense that enables the analysis of data from the latest generation of high-throughput genotyping platforms; Translational Research solution that provides a framework to integrate and analyze clinical, patient specimen, and experimental data for clinical translational research; BioSense that provides an interactive analytics environment for designing and executing bioinformatics solutions ranging from sequence analysis to microarray informatics and remote database annotation; and ChemSense that provides a vendor-neutral environment for designing and executing cheminformatics solutions. In addition, it offers business intelligence products and solutions, such as asset management, credit risk, CRM analytics, operational risk, and Siebel edition datasheet solutions. Further, the company provides consulting, workshop, and training services. The company serves pharmaceutical, biotechnology, consumer goods, healthcare, financial services, manufacturing, and communications companies. It has operations in the United Kingdom, the United States, Germany, and Japan. InforSense, Ltd. was founded in 1999 and is based in London, the United Kingdom with additional offices in Cambridge, Massachusetts; and Shanghai, China. As of June 2009, InforSense Ltd. operates as a subsidiary of ID Business Solutions Ltd.

Lontra is a leading engineering, manufacturing and digital services business delivering revolutionary air and gas compressors. The company is backed by world-class technical and commercial partners, including Industrial Air Centers, Universal Wolf, Sulzer, Shield Engineering Group, ABB, SKF, Severn Trent Water and Yaskawa. The company's flagship product, the award-winning and patented Blade Compressor® is the first widely applicable new compressor design in over 80 years. The technology is proven to be up to a third more efficient than its competitors, offering incredible energy savings and delivering significant improvements in reliability. Now developing new technologies and expanding into new industries and compressor applications. These include general manufacturing, cement, food and drink, pharmaceutical, industrial wastewater, drinking water and power generation. Lontra has attracted wonderful support in terms of grants and awards from Innovate UK, Horizon2020, Edie, IMechE, Royal Academy of Engineering, The Carbon Trust, and Severn Trent Water. Most recently winning the 2020 IMechE Award for Innovation in Bulk Materials and Handling.

Midaz Lasers manufactures high power diode-pumped solid state laser products for micromachining applications.